Kura Oncology Inc To Host ASH Virtual Investor Event Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Li Watsek - Cantor Fitzgerald - Analyst : Hey, good morning and congrats on the data. Troy, can you talk a little bit about your confidence in frontline is even combination? And how should we think about the rates too from the ease event complete data that you just shared in the salvage setting?

Question: Li Watsek - Cantor Fitzgerald - Analyst : Okay. And I guess for both doctors, can you share your thoughts on the potential of using MRD negativity as a potential target and point in front line? And what is your view on using flow versus PCR based methods to measure MRD?

Question: Li Watsek - Cantor Fitzgerald - Analyst : Thank you.

Question: Jonathan Chang - Leerink Partners - Analyst : Hi guys. Good morning, and thanks for taking my questions. For the docs on the call, given the totality of the data sets across the menin space, what do you see as the key differences on the safety profile between the menin inhibitors in development? And how could that impact, if any, the opportunity in frontline combinations? Thank you.

Question: Jonathan Chang - Leerink Partners - Analyst : Understood. Thanks for taking the questions.

Question: Jason Zemansky - BofA Securities - Analyst : Good morning. Congratulations on your conference updates, and thank you so much for taking our question. I wanted to circle back on the relapsed, refractory data, and maybe this is one for your KOLs. But can you speak to what we're seeing and the responses between the [pen] experienced and naive patients in the KMT2A population? Why do you think we're seeing these trends appreciating that the data are still somewhat early?

Question: Jason Zemansky - BofA Securities - Analyst : Got it. I appreciate the in depth color.

Question: Roger Song - Jefferies - Analyst : Great. Congrats for the data update in ASH, and then thanks for taking the question, two from us. One is multipart question related to the transplant and the post-transplant maintenance. So just curious for doctors, following zifto treatment, how you make a decision you will move the patient into transplant, and how you're going to make decision, put them back on zifto post-transplant. Specifically, the difference between the NPM1 and KMT2A patient? And then if you have any experience with under menin inhibitor, how do you see the difference between zifto versus other menin inhibitor in terms of the decision for transplant and the post-transplant maintenance? And then I have a follow-up question. Thank you.

Question: Roger Song - Jefferies - Analyst : Yes. Thank you. Thanks for all the detailed comments. So my next question related to the R&R, the relapsed and refractory population. So given this, the most updated of the major zifto combination data, what is the read through from this trial to the ongoing pivotal monotherapy for zifto? If you can comment on the patient baseline, maybe prior therapy, and then maybe to accompany how confident you are around the guidance or the expectation you have been giving us in terms of 20% to 30% CR, CRH for zifto monotherapy in the R&R population? Thank you.

Question: Roger Song - Jefferies - Analyst : Got it. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 09, 2024 / 1:00PM, KURA.OQ - Kura Oncology Inc To Host ASH Virtual Investor Event Call

Question: Peter Lawson - Barclays - Analyst : Great. Thank you so much. Thanks for all the detail. And I've got a couple of questions for the KOLs in the call. Firstly would be when a patient discontinues, when you're thinking about the frontline from your experience with relapse, refractory, would you typically discontinue the patient for the chemo component or do the menin component or both? And then just the idea of delaying transplant in the frontline setting, do you think that's becoming more accepted by your colleagues of when patient hits MRD negative? So if you kind of talk through that. Thanks so much.

Question: Peter Lawson - Barclays - Analyst : Great. Thank you so much.

Question: Reni Benjamin - JMP Securites LLC - Analyst : Hey, good morning guys. Thanks for taking the questions, and congratulations on the data. I may have missed this, but can you talk a little bit about the MRD negativity rates and the zifto, ven, aza combo in the relapsed, refractory setting? And I guess as we think about the frontline opportunity, what kind of degree of improvement would you like to be seeing in the frontline opportunity versus just ven, aza alone? And we're seeing some competitive data in the landscape coming out where you're seeing like 95% CRC rate for menin with ven, aza in the frontline. I kind of feel like there's not much more improvement that we can see. So you think in the frontline setting, this largely becomes a competition from a safety perspective as opposed to efficacy? And then I have a quick follow-up.

Question: Reni Benjamin - JMP Securites LLC - Analyst : Sure. I guess I'm looking for from the KOLs, maybe what degree of improvement, right, might you see over ven, aza by itself when you add something like zifto? There's been some competitive data, right, that's come out showing a menin inhibitor in combination with ven, aza in the front line, showing like a 95% CRC rate, right? And I kind of feel like there's not much more in terms of improvement that other agents might be able to bring. So in the frontline setting, if you get similar sort of efficacy, which I'm going to assume that across the class, you might see similar efficacy, does it just become a competitive -- just a competitive landscape ultimately focus primarily on safety in the frontline issue, and that's what drives the incorporation of the drug? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 09, 2024 / 1:00PM, KURA.OQ - Kura Oncology Inc To Host ASH Virtual Investor Event Call

Question: Reni Benjamin - JMP Securites LLC - Analyst : Got it. All right. Thank you very much for that. And maybe just a quick follow-up. In the ven, aza combo, I believe about some around 40% of the NPM1 patients had three co-mutations as well. I'm kind of curious was there any insights or read through that you saw from this data that you might employ in KOMET-008?

Question: Reni Benjamin - JMP Securites LLC - Analyst : Excellent. Thank you guys very much.

Question: Phil Nadeau - TD Securities - Analyst : Good morning. Thanks for taking our questions. Just two from us. I guess first on the data presented in the relapse, refractory population, there did seem to be pretty meaningful difference in efficacy between the KMT2A population and NPM1 population. So we're curious to get your thoughts on why that might be particularly given that it looked like differentiation syndrome was manageable in both populations? That's the first question. And then second question for management. Could you discuss a little bit more about how the 600 milligram dose was chosen? I guess to RI, we don't see a lot of difference in the data between the doses. So was the 600 milligram really the default and was going to be chosen as long as there's no safety issues preventing it? Thanks.

Question: Phil Nadeau - TD Securities - Analyst : That's very helpful. Thanks for taking our questions.